DPP4 inhibitor saxagliptin which increases the level of glucagon-like peptide-1 (GLP-1) and ameliorates T2DM, has become a valuable candidate as a disease-modifying agent in the treatment of AD. The gene discussed is DPP4; the disease is Alzheimer disease.